C07K 16/18
Against material from animals or humans
Official title: against material from animals or humans
C07K16/18 (Against material from animals or humans) appears on 36,051 US grants and 65,766 published applications in this corpus.
Search patents in C07K- Granted patents
- 36,051
- Published applications
- 65,766
- Assignees
- 11,157
- Inventors
- 74,913
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 10 | 0 |
| 1977 | 4 | 0 |
| 1978 | 7 | 0 |
| 1979 | 8 | 0 |
| 1980 | 8 | 0 |
| 1981 | 12 | 0 |
| 1982 | 26 | 0 |
| 1983 | 16 | 0 |
| 1984 | 33 | 0 |
| 1985 | 35 | 0 |
| 1986 | 38 | 0 |
| 1987 | 83 | 0 |
| 1988 | 74 | 0 |
| 1989 | 120 | 0 |
| 1990 | 102 | 0 |
| 1991 | 115 | 0 |
| 1992 | 150 | 0 |
| 1993 | 217 | 0 |
| 1994 | 179 | 0 |
| 1995 | 184 | 0 |
| 1996 | 294 | 0 |
| 1997 | 535 | 0 |
| 1998 | 691 | 0 |
| 1999 | 604 | 0 |
| 2000 | 482 | 0 |
| 2001 | 486 | 150 |
| 2002 | 455 | 890 |
| 2003 | 367 | 2434 |
| 2004 | 378 | 1176 |
| 2005 | 331 | 1385 |
| 2006 | 539 | 1344 |
| 2007 | 671 | 1348 |
| 2008 | 715 | 1345 |
| 2009 | 737 | 1796 |
| 2010 | 905 | 1819 |
| 2011 | 960 | 1923 |
| 2012 | 1019 | 1842 |
| 2013 | 1171 | 2033 |
| 2014 | 1252 | 2495 |
| 2015 | 1379 | 2437 |
| 2016 | 1506 | 2827 |
| 2017 | 1645 | 2897 |
| 2018 | 1620 | 3121 |
| 2019 | 1832 | 3658 |
| 2020 | 2086 | 3942 |
| 2021 | 2114 | 4326 |
| 2022 | 2040 | 4367 |
| 2023 | 1901 | 4259 |
| 2024 | 2159 | 4686 |
| 2025 | 2208 | 4058 |
| 2026 | 1548 | 3208 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C07K 16/28Against receptors, cell surface antigens or cell surface determinants24,500
- C07K 16/24Against cytokines, lymphokines or interferons4,444
- C07K 16/22Against growth factors2,796
- C07K 16/32Against translation products of oncogenes2,531
- C07K 16/26Against hormones913
- C07K 16/36Against blood coagulation factors501
- C07K 16/20From protozoa322
- C07K 16/34Against blood group antigens174
Recent patents
- Combination therapy of PD-1 axis binding antagonists and LRRK2 inhitibors6 Oct 2026US 12,751,956 B2Hoffmann-La Roche Inc.
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- Immunostimulatory adjuvants6 Oct 2026US 12,752,000 B2Orionis Biosciences BV
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Extracellular vesicles for the delivery of payloads to eukaryotic cells8 Oct 2026US 2026/0306416 A1Alaya.bio Inc.
- Compositions and methods for treating cancer by targeting bach18 Oct 2026US 2026/0306455 A1
- Treatment of clonal hematopoietic disorders using kinase inhibitors8 Oct 2026US 2026/0306462 A1
- Prolyl hydroxylase domain-containing protein (phd) inhibitors, combinations and uses thereof8 Oct 2026US 2026/0306471 A1Insilico Medicine IP Limited
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
Most cited
By later US patents
- Recombinant immunoglobin preparations4,785US 4,816,567 AGenentech, Inc. · 1989
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Single polypeptide chain binding molecules2,454US 4,946,778 AGenex Corporation · 1990
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997